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TITLE:  Chemotherapy-related damage to ovarian reserve in childhood cancer 
survivors: interpreting the evidence.  
 
 
Abstract 
Chemotherapy during childhood damages ovarian reserve and can affect future fertility However, 
recent large epidemiological studies showed that the detrimental impact on fertility is less severe if 
women seek for pregnancy at a younger age. To explain this observation, we hypothesize that the 
detrimental effects of previous chemotherapy on the ovarian reserve may be attenuated in young 
adults for two main reasons. Firstly, recent evidence showed that the amount of ovarian reserve is 
not a critical factor for effective natural conceptions. Provided that the residual ovarian reserve 
allows regular ovulatory cycles, the chances of pregnancy are similar in women with intact or 
reduced ovarian reserve. Secondly, ovarian reserve depletion appears to be a phenomenon that is 
inversely related to the residual ovarian reserve rather than to age. From a mathematical 
perspective, this kind of regulation intrinsically attenuates the effects of an early loss of a significant 
amount of primordial follicles. In conclusion, the detrimental effects of chemotherapy on natural 
fertility may be less severe if women with a history of chemotherapy during childhood seek for 
pregnancy early. This information should be part of the counseling.  
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Introduction 
Chemotherapy damages ovarian reserve and may compromise future fertility in childhood cancer 
survivors (Table 1) [1-9]. The magnitude of the damage depends on the specific agents used, with 
alkylating agent being the most harmful, and the total doses administered. High doses multi-agents 
regimens such as those required for bone marrow transplantation almost invariably cause immediate 
premature ovarian insufficiency (POI). To date, the mechanisms of the chemotherapy-related injury 
to ovarian reserve have been only partially elucidated and may differ according to the specific agent 
used [10-12]. They include the accelerated recruitment of primordial follicles (“burn-out” effect) 
[13], the impairment of the local vascularization [14] and a direct damage to oocytes or granulosa 
cells [10]. 
During the last two decades, outstanding progresses have been made to reduce the risk of 
childlessness in childhood cancer survivors. The cryopreservation of ovarian cortex or oocytes (if 
post-pubertal) prior to initiate the oncologic treatments have actually improved the future chances 
of parenthood in these women [11,15,16] However, to date, the precise role of fertility preservation 
procedures remains to be determined [11,15]. To note, the use of these techniques poses some 
additional technical and ethical issues in minors [17,18]. Further evidence on this multifaceted topic 
and a more in-depth understanding of the mechanisms of damage is needed. 
 
New epidemiological evidence 
Two recent large cohort studies reporting on long-term fertility in childhood cancer survivors 
provided some enlightening new information on the role of women age at the time of pregnancy 
seeking [5-6].  
Specifically, in the first study, Bramswig et al. reported on parenthood of 467 Hodgkin’s lymphoma 
survivors who received chemotherapy before 18 years of age between 1978 and 1995 [5]. The 
median length of follow-up was 20 years (Interquartile range-IQR: 16-25). Two-hundred twenty-
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eight women had 406 children (median 1.8 children per mother). The cumulative incidence of 
parenthood was 67% (95%CI: 64-75%) at 28 years of follow-up and 69% (95%CI: 61-74%) at 40 
years of age. When comparing these data to the local national frequency of parenting and stratifying 
per class of age, no statistically significant difference emerged up to 40 years. A significant 
reduction in cumulative pregnancy rate was observed only in cancer survivors aged 40-44 years [5].  
The second study reported data from the US Childhood Cancer Survivor Study cohort. It did not 
exclusively focused on Hodgkin’s lymphoma but, conversely, to all childhood cancer survivors 
(only women receiving radiotherapy to the pelvis or to the brain were excluded) [6]. The authors 
actually collected information from 5,298 cancer survivors who were treated before age 21 between 
1970 and 1999. The median follow-up was 8 years (IQR: 4-12). Controls were sisters of survivors. 
Overall, the Hazard Ratio (HR) of live birth was 0.82 (95%CI: 0.76-0.89). More specifically, it was 
0.87 (95%CI: 0.80-0.95) in women aged less than 30 years and then dropped to 0.63 (95%CI: 0.53-
0.76) in those aged 30 to 44 years [6].  
Overall, the evidence emerging from these two cohort studies tends to confute the simplistic view 
suggesting a direct relation between the amount of ovarian reserve and fertility. Ovarian reserve is 
indisputably damaged by chemotherapy (even if with relevant variations according to the regimens 
used), but the impact on fertility appears modest in earlier ages. In the majority of cancer survivors, 
the chances of parenthood may actually be impaired only at later age.  
In our opinion, the attenuated detrimental effects of chemotherapy in young age suggests two main 
considerations that may be clinically useful for physicians involved in the field; 1) the importance 
of distinguishing the amount of the residual ovarian reserve and the quality of the oocytes, 2) a non-
linear vision of the of the rules that guide age and chemotherapy-related loss of ovarian reserve. 
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Quality of oocytes and ovarian reserve 
Natural fertility progressively declines from the early thirties and terminates at about 41 years of 
age [19,20]. Thereafter, regular cycles continue for about 5 years but the quality of the ovulated 
oocytes is hampered and does not allow to achieve live births. Finally, cycles become irregular and 
frequently anovulatory until menopause that occurs at about 51 years of age [19].     
These biological events are accompanied by a progressive decline of the ovarian reserve. The 
advent of menopause and the preceding irregular cycles are direct consequences of the depletion of 
the ovarian reserve but the progressive decline in natural fertility in the thirties and early forties has 
a different explanation. A growing body of biological and clinical evidence actually supports the 
preponderant role of age rather than residual ovarian reserve as a crucial factor to explain the 
decline of natural fertility. In other words, the quality of the oocytes rather than the quantity of the 
residual primordial follicles would determine the chances of motherhood. Even if an initial study 
suggested some relation between the amount of the residual ovarian reserve and natural fertility in 
women older than 35 years [21], five subsequent independent studies in the general population 
failed to show any association between ovarian reserve and natural fertility [22-26]. This evidence 
is summarized in Table 2.  
The predominant role of age over that of ovarian reserve may partly explain the results of the two 
above-mentioned epidemiological studies that do not support the notion of a major fertility 
impairment in cancer survivors until older ages. In fact, one may envisage that in some cases 
chemotherapy may reduce ovarian reserve and anticipate menopause without affecting fertility. 
Indeed, since natural fertility ends at a mean age of 41 regardless of the subsequent age of 
menopause, a clinically relevant impairment of the ovarian reserve that takes place after age 41 may 
be unremarkable for the sake of childbearing. Moreover, even in women who had a more significant 
iatrogenic reduction of ovarian reserve and who will enter menopause before 41 years, parenthood 
may not be affected provided they seek pregnancies early, thus before facing the consequences of 
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ovarian reserve exhaustion (anovulation, irregular menstrual cycles and finally definitive 
amenorrhea).  
Noteworthy, this is very similar to what is observed in women with POI. In fact, the vast majority 
of these women fulfill their reproductive whishes [27]. Only those who excessively delay pregnancy 
seeking or who enter menopause at a very young age may ultimately remain childless. Noteworthy, 
the median time between last conception and amenorrhea was 4 years (IQR: 1-8 years), thus 
remarkably less than the 10 years interval reported for women entering menopause at a normal age 
(one quarter of studied patients actually entered menopause within one year after delivery). To note, 
this result was observed in a modern Western population with low fertility index, thus leading to 
over-estimate the time between last conception and menopause. In addition, the study did not also 
show increased time to pregnancy in POI women [27].  
On the other hand, it has to be recognized that even if the available evidence tends to support the 
idea that fertility and ovarian reserve should be disjointed, specific evidence in the peculiar group of 
childhood cancer survivors is needed. To note, Letourneau et al. [28] reported high rates of 
infertility in cancer survivors resuming regular menstrual cycles after chemotherapy (15-27% 
according to the different oncologic diagnoses). However, the study design was not designed to 
disentangle the independent effect of age and ovarian exhaustion. 
 
Models of ovarian reserve depletion 
The scant relevance of reduced ovarian reserve on the chances of natural pregnancy may explain 
only in part the attenuation of the impact of previous chemotherapy on fertility documented in the 
two above-mentioned cohort studies [5,6]. Other factors may also contribute. To note, even if not 
fully consistent and inevitably linked to the specific disease and type and doses of chemotherapy, 
the available literature generally documents that the magnitude of the damage to the ovarian reserve 
is remarkable, even for non-myeloablative regimens [10,16]. In vivo xenograft studies using human 
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ovarian cortex showed dramatic toxic effects, with a reduction of the pool of primordial follicles 
reaching 50-100% according to the agents (or regimen) and doses used [29,30]. Albeit more 
limited, there is also some direct histological data on the density of primordial follicles in cancer 
survivors [10,31,32]. In an in-vivo study of 26 women treated for different malignancies who 
subsequently underwent ovarian biopsies, the follicular density appears to be halved [31], but data 
is controversial [32]. In contrast, evidence from surrogate measurements of ovarian reserve such as 
serum FSH, serum AMH and Antral Follicle Count-AFC is larger. Most recent evidence on this 
issue are presented in Table 3 [33-40]. Even if the magnitude of the estimated damage differs, the 
available studies consistently support a significant damage. To note, these studies may 
underestimate the detrimental effects of chemotherapy since women with POI are generally 
excluded. 
To explain this apparent paradox (i.e. a relevant biological damage but a modest clinical effect), one 
may speculate on the mathematical rules that regulate the exhaustion of the pool of primordial 
follicles. The rate of decline of the ovarian reserve has been a topic of controversy [41-47]. 
Differences in the outcome studied (FSH, AMH, antral follicle count or histological count of the 
primordial follicles) could explain at least in part this controversy. Of utmost relevance here is that 
the loss of primordial follicles (i.e. the real physiological unit of the ovarian reserve) is not linear 
[47]. A systematic review on this issue showed that the absolute rate of loss per unit of time is 
higher at younger ages (the vast majority of the ovarian reserve is actually lost before menarche) 
and then progressively decreases [46]. In this context, two different models of ovarian reserve 
depletion may be hypothesized: 1) age-dependent loss and, 2) ovarian reserve-dependent loss. In 
the first model, the rate of primordial follicles loss would be exclusively guided by age. The crude 
loss would decrease with age, but this rate would be fixed for every specific age. Conversely, in the 
second model, the loss would be guided by the amount of the residual pool. The crude loss of 
primordial follicles would be inversely related to the remnant pool rather than to a specific age.  
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The long term detrimental effects of chemotherapy on ovarian reserve are expected to be markedly 
different according to the postulated model of primordial follicle loss. If the loss is exclusively 
driven by age, the impact of a damage to the ovarian reserve would be dramatic, while, in the 
second case, it would be significantly attenuated. From a mathematical point of view, the two 
models can be simplistically presented as follows: 
Age-dependent loss:       From   Y = 1 / X  to : Y = (1 / X) – A 
Ovarian reserve-dependent loss  From   Y = 1 / X  to : Y = 1 /( X + A) 
Where Y is the residual ovarian reserve, X is time (age) and A is a constant indicating the amount 
of chemotherapy-related damage.  
These two possibilities are illustrated in Figure 1. In the first scenario (age-dependent loss), one 
would observe definitive ovarian reserve impairment within a very short period of time. 
Conversely, in the second scenario (ovarian reserve-dependent loss), despite the similar immediate 
loss, clinically significant impairment of ovarian reserve would occur much later and the advent of 
the clinical events associated to ovarian reserve impairment (irregular cycles, menopause and 
infertility) would be only marginally anticipated.  
Overall, the second model appears to better fit with the available epidemiological evidence and 
would explain the above emphasized contrast between the remarkable impact of chemotherapy on 
ovarian reserve and the relatively mild clinical impact on fertility, that becomes evident only at 
older ages. 
 
Comment 
Oocyte quality and thus age is more important than ovarian reserve for natural conception, provided 
there is a sufficient amount of residual primordial follicles to ensure regular menstrual cycles. 
Moreover, loss in ovarian reserve with age follows a complex non-linear model that appears to 
depend on residual ovarian reserve and that actually attenuates the impact of chemotherapy-related 
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injury. These two observations may explain the contrast between the relevant crude amount of 
primordial follicle loss associated with chemotherapy and the relatively milder clinical impact. 
Even if these considerations are mainly theoretical and lack sufficient evidence to elaborate a 
precise mathematical model, they provide a reasonable explanation for the available 
epidemiological evidence and may have research and clinical implications. 
Firstly, they highlight the importance of improving our capacity to predict fertility impairment at 
the time of cancer diagnosis in children and adolescent. The availability of a reliable and validated 
tool to predict future fertility would consent a more accurate counseling and would improve the 
shared decision-making process. To date, the only validated criteria are the so-called “Edinburgh 
criteria” [48]. The authors reported a risk of POI in women who do and do not fulfill the criteria of 
35% and 1%, respectively (p<0.001). These results are of particular relevance considering that only 
8% of young girls with cancer fulfilled these criteria and should be scheduled for fertility 
preservation. On the other hand, these criteria lack external validation and provide evidence on the 
rate of POI rather than on childbearing. Not recommending fertility preservation procedures 
exclusively based on the Edinburg criteria may be questionable.  
Secondly, our considerations highlight the importance of an early reproductive counseling of 
childhood cancer survivors. Postponing motherhood is a diffuse demographic phenomenon of 
Western countries that may impact on the ultimate chances of pregnancy in women in general [49]. 
This social trend may be even more detrimental for childhood cancer survivors whose period of 
fecundity may be shortened. In fact, if on one hand this reduction may be modest on average, on the 
other side it can greatly impair the reproductive performance if affected women delay pregnancy 
seeking. In fact, more and more women are currently seeking pregnancy in the upper boundary of 
the fertility window [49]. Cancer survivors who do so may be inevitably exposed to a major risk of 
childlessness. On the other hand, even if there is evidence that women with a history of cancer may 
face fertility problems in their own way [50], one cannot oblige them to behave differently than the 
9 
 
general population and to anticipate pregnancy seeking. For this reason, the considerations 
expressed in this opinion paper should not be used per sé to argue against the use of fertility 
preservation techniques in girls or adolescent planned for chemotherapy. Educating to look for a 
pregnancy at a younger age is wise, but one has to accept that this counseling will be followed in a 
limited percentage of women. 
Thirdly, one may also consider to perform fertility preservation techniques after the end of the 
oncologic treatments, once survivors reach the legal age of majority. In childhood survivors, this 
option was shown to be feasible and deserves consideration [18]. Young women with substantial 
but not definitive damage to the ovarian reserve may benefit from this approach. It has some 
indisputable advantages over fertility procedures done at the time of cancer diagnosis, including 
some ethical issues. However, the use of post-chemotherapy fertility preservation techniques for 
adult women with reduced but not compromised ovarian reserve should be currently considered a 
second-line option and needs validation. Notably, eligible women  are also expected to be those 
collecting a low number of eggs. Unfortunately, even if a reduced ovarian reserve may be 
unremarkable for natural conception, it may hamper ART success in general (and thus also the 
success of oocyte storage programs) [51]. The number of stored oocytes is actually an important 
determinant of success and women previously exposed to chemotherapy are at higher risk of 
impaired egg retrieval. The possibility to perform several rather than only 1-2 cycles of ovarian 
hyper-stimulation cannot be expected to fully overcome a condition of impaired ovarian reserve. 
Our general reasoning is not definitive and should be viewed as speculative. The utility of fertility 
preservation cannot be questioned based on the available evidence. In particular, there is the need 
for further and more informative studies on the impact of chemotherapy. The findings emerging 
from the two large cohort studies [5,6] are exposed to a bias of selection (only survivors were 
included) and were obtained in selected populations (Hodgkin’s lymphoma in the first study and 
cancers not requiring radiotherapy to the pelvis or the brain in the second study). Moreover, the 
10 
 
attitude of cancer survivors towards motherhood may be influenced by their personal oncologic 
history and this could impact on the propensity to seek for pregnancy [50]. Both studies did not 
address this possible confounder. Finally, it is noteworthy that our interpretation of the evidence is 
exclusively based on age and the pool of remnant primordial follicles. The complete figure is 
presumably more complicated [52,53]. For instance, it has recently been reported that, despite being 
normally fertile, women with very low serum AMH (<0.4 ng/ml) face a higher risk of miscarriage 
[54]. Moreover, not all evidence concord on the most reliable model to describe the rate of follicle 
primordial loss over the years [51,52].   
In conclusion, the advent of large cohort studies on the long-term impact of chemotherapy in 
childhood cancer survivors is opening new perspectives. Disentangling the mechanisms linking 
chemotherapy, damage to the ovarian reserve and subsequent natural fertility may open new 
avenues of research and may influence clinical practice.  
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Figure legend 
 
Figure 1:  Impact of chemotherapy on ovarian reserve according to the hypothesized 
mathematical model guiding the loss of the primordial follicle pool. The model based on the crucial 
role of age is represented in the upper panel (panel A). The model based on the crucial role of the 
remnant ovarian reserve is represented in the lower panel (panel B). The plain curves represent the 
decline in ovarian reserve in basal situation (referral lines). The dotted curves represent the decline 
in ovarian reserve in girls exposed to chemotherapy: for simplicity we postulated a halving of the 
residual ovarian reserve at the starting point. In panel A, the dotted curve actually corresponds to a 
vertical shift (downwards) of the referral curve. In panel B, the dotted curve actually corresponds to 
a lateral shift (to the left) of the referral curve. These shifts are represented with dotted arrows. The 
dashed horizontal lines represent the threshold of residual ovarian reserve that is required to ensure 
ovulatory regular cycles. Even if the notion that the decrease in ovarian reserve follows exponential 
rules is based on a published model [46], all the curves represented in these figures are theoretical 
and, therefore, no precise units are reported. However, the scales of the two axes have to be 
considered linear. 
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Table 1.  Recent epidemiological studies reporting on fertility in childhood and young adult cancer survivors  
     
Study Design Diagnoses of cases N. exposed women (age) Main results 
     
Madanat et al., 2008 [1] Linking of Finnish registers of cancer and the 
one of central population. Comparisons were 
made with siblings identified with  the second 
register. 
All cancers 1,334 (0-14 years) + 
1,254 (15-19 years) 
RR=0.62 (95%CI: 0.56-0.68) for age 0-14 
and RR=0.64 (95%CI: 0.58-0.70) for age 
15-19.  
Reulen et al., 2009 [2] British cohort study with active follow-up 
(quesyionnaires). Comparison with the 
expected pregnancy rates in the general 
population 
All cancers 10,483 (0-14 years) O/E: 0.64 (96%CI: 0.62-0.66) 
Stansheim et al., 2011 [3] Linking of Norway registers of cancer and 
birth. Comparison with matched unexposed 
women of the National register. 
All cancers not reported (subset 
of women aged 16-
25 years) 
HR=0.67 (95%CI: 0.63-0.73) 
Pivetta et al., 2011 [4] Multicenter hospital-based italian cohort study. 
Comparison with the expected pregnancy rates 
in the general population 
All cancers 1,888 (0-14 years) O/E: 0.57 (96%CI: 0.53-0.62) 
Bramswig et al., 2015 [5] Prospective German cohort study (patients 
included in 5 trials). Comparison with the 
general population. 
Hodgkin's lymphoma 554 (0-17 years) No significant difference with the 
exception of those seeking at 40-44 years 
(61% vs 78%, p=0.001). 
Chow et al., 2016 [6] Cohort study from 27 Istitutions in USA and 
Canada (CCSS: childhood Cancer Survivor 
Study). Controls were siblings. 
All cancers (exclusion 
of girls requiring brain 
or pelvis radiotherapy) 
2,455 (0-20 years) HR=0.82 (95%CI: 0.75-0.90) 
Armuand et al., 2017 [7] Use of the Sweden national patient register. 
Comparison with matched unexposed women 
of the general population (same register). 
All cancers 552 (0-20 years) HR=0.82 (95%CI: 0.72-0.95) 
Anderson et al., 2018 [8] Linking of Scottish registers of cancer, 
pregnancies and death. Comparison with the 
expected pregnancy rates in the general 
population 
All cancers 1,638 (0-14 years) + 
2674 (15-24 years) 
SIR=0.72 (95%CI: 0.66-0.78) for age 0-14 
and SIR=0.69 (95%CI: 0.66-0.72) for age 
15-24.  
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Only studies published during the last decade are included.    
If identified studies overlapped for study population, only the most recent one was included.   
SIR: Standardized Incidence Ratio. HR: Hazard Ratio. O/E: Observed/expected ratio   
 
21 
 
 
Table 2.  Studies on ovarian reserve and natural fertility    
     
Study Design Sample size Outcome  Main findings 
     
Navot et al., 1987 [21] Cohort of women > 35 years with unexplained 
infertility divided in two groups based on CCCT 
(day 10 FSH> 26). 
18 women with low 
ovarian reserve and 35 
with normal ovarian 
reserve 
Pregnancy 
rate 
6% vs 42% (p<0.05) 
Hagen et al., 2012 [22] Cohort of women recruited prior to initiate 
pregnancy seeking and followed until pregnancy or 
for six menstrual cycles. 
186 divided into low 
(n=36), medium (n=113) 
and high (n=37) AMH. 
Fecundity 
rate per 
month 
Low vs medium AMH: 0.9 (95%CI: 
0.5-1.5) (p=ns). High vs medium 
AMH: 0.7 (95%CI: 0.4-1.1) (p=ns). 
Streuli et al., 2014 [23] Correlation of AMH with time to pregnancy in a 
cohort of pregnant women. 
86 women, of whom  82% 
within 6 months. 
Time to 
pregnancy  
Correlation between AMH and time to 
pregnancy: r=-0.10 (p=ns) 
Somigliana et al., 2015 [24] Case-control study of pregnant women comparing 
those who were subfertile (pregnancy seeking > 1 
year) to those who were fertile (pregnancy seeking < 
1 year) .  
76 subfertile cases and 76 
age-matched controls 
AMH  2.6 (1.6–4.0) vs 2.8 (1.4–4.3) (p=ns) 
Steiner et al., 2017 [25] Cohort of women seeking pregnancy 610 women, of whom 487 
(80%) conceived. 
Hazard 
ratio of 
conceiving 
Low vs medium AMH: 1.2 (95%CI: 
0.9-1.6) (p=ns). High vs medium 
AMH: 0.9 (95%CI: 0.6-1.2) (p=ns). 
High vs low FSH: 1.2 (0.9-1.6) (p=ns) 
Greenhood et al., 2018 [26] Case-control study comparing women with 
unexplained infertility and healthy ovulatory 
controls not seeking pregnancy 
227 cases and 226 
controls 
AMH and 
AFC 
AMH: 5.9 ± 5.2 vs 5.2 ± 3.9 ng/ml 
(p=ns). AFC: 21 ± 11 vs 17 ± 9 (p=ns) 
          
     
AMH is reported as ng/ml, FSH is reported as IU/L. CCCT: Clomiphene Citrate Challenge Test 
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Table 3.  Controlled studies on the impact of chemotherapy on ovarian reserve  
      
Study N. cases Age (years) 
N. 
controls Outcome Main findings 
a 
      
Lie Fong et al., 2009 [32] 182 25 (17-47) 42 AMH 1.7 (<0.1-19.9) vs 2.1 (0.1-7.4):  p=ns 
Gracia et al., 2012 [33] 71 25.7 (24.2-27.2) 67 FSH 11.1 [9.5-13.1] vs 7.2 [6.0-8.8]: p=0.001 
    AMH 0.8 [0.6-1.1] vs 2.8 [2.1-4.0]: p<0.001 
    AFC 15 [11-18] vs 27 [23-31]: p<0.001 
Dillon et al., 2013 [34] 84 26 [24-27] 98 FSH 13.9 [10.4-16.4] vs 7.2 [6.6-8.0]:  p<0.001 
    AMH 0.7 [0.5-1.] vs 2.4 [2.0-2.7]:  p<0.001 
    AFC 11 [9-14] vs 23 [20-26]:  p<0.001 
El-Shalakany et al., 2013 [35] 30 19.1 ± 4.6 30 FSH 8.4 ± 1.5 vs 3.3 ± 0.4:  p=0.001 
    AMH 1.5 ± 0.7 vs 2.0 ± 1.0:  p=0.02 
Krawczuk-Rybak et al., 2013 [36] 83 18.9 ± 5.0 38 FSH 12.2 ± 19.4 vs 5.4 ± 1.9:  p=0.001 
    AMH 2.3 ± 2.0 vs 3.8 ± 1.7:  p=0.001 
Johnson et al., 2014 [37] 84 25 (15-39) 115 AMH 0.7 [0.5-0.9] vs 2.3 [2.0-2.6]:  p<0.05 
    AFC 16 [14-19] vs 27 [25-30]:  p<0.05 
Akar et al., 2015 [38] 41 15.0 ± 2.4 44 FSH 13.5 ± 16.2 vs 7.3 ± 2.7:  p=0.017 
    AMH 1.6 ± 0.4 vs 1.7 ± 0.3:   p=ns 
    AFC 3.4 ± 3.3 vs 8.6 ± 3.5:  p<0.001 
Thomas-Teinturier et al., 2015 [39] 105 25 [17-49] 20 AMH 1.5 [0-13.7] vs 3.1 [0.5-6.6]:  p=0.003 
            
      
Only studies in childhood or young women cancer survivors and comparing data to a control group were included.  
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Data is reported as median (range) or median [5-95th centile] or mean ± SD.  
a Data was reported firstly for cases and secondly for controls.    
AMH was reported as ng/ml and FSH as IU/L.    
AFC was reported only if collected by transvaginal ultrasound.   
 
    
 
